For example, the human epidermal growth factor receptor 2 (HER2) has become now a new marker of gastric cancer following evidence-based principles [12].Adding trastuzumab to standard chemotherapy could change the poor survival of patients with HER2-positive metastatic gastric cancer [13]–[15]. Here, ERBB2 is linked to gastric cancer.